Rezafungin to treat Pneumocystis pneumonia in adults with HIV
Part of Infections, Lungs & breathing clinical trials.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re at least 18 years old and can sign consent (or a legally approved representative can).
- You have confirmed HIV infection, and you’re diagnosed with PCP before starting the study.
- If you can have a pregnancy, you must use very effective birth control during the study and for 30 days after the last dose.
- If you’re male and can father a pregnancy, you must not donate sperm and either avoid sex with someone who could become pregnant or use condoms during the study and for 120 days after the last dose.
- Your blood counts must be high enough: neutrophils at least 1,000 and platelets at least 50,000.
- Your kidneys and liver must be healthy enough (very low kidney function or significant liver problems can disqualify you).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This trial tests a new inhaled medicine (caspofungin) added to standard treatment for Pneumocystis pneumonia, a serious lung infection. It may help fight the infection more effectively while you are already receiving oxygen and standard antibiotics.
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
This trial tests whether a medicine called rezafungin can help prevent serious fungal infections in people who have received a liver transplant. If you have certain risk factors, this study may offer extra protection against infections.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
Hear when a new Pneumocystis Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.